Get the Stockscreener App
1.55
3.33%
0.05
Minerva Neurosciences Inc stock is traded at $1.55, with a volume of 3,931.
It is up +3.33% in the last 24 hours and down -7.19% over the past month.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
See More
Previous Close:
$1.50
Open:
$1.53
24h Volume:
3,931
Relative Volume:
0.28
Market Cap:
$10.76M
Revenue:
-
Net Income/Loss:
$-33.65M
P/E Ratio:
-0.3483
EPS:
-4.45
Net Cash Flow:
$-20.83M
1W Performance:
+6.16%
1M Performance:
-7.19%
6M Performance:
-31.26%
1Y Performance:
-33.48%
1-Day Range:
$1.5144
$1.55
1-Week Range:
$1.35
$1.55
52-Week Range:
$1.15
$3.69
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1601 TRAPELO ROAD, WALTHAM, MA
Compare NERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
1.54 | 10.14M | 0 | -33.65M | -20.83M | -4.45 |
|
ONC
Beone Medicines Ltd Adr
|
245.79 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.73 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.61 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.59 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at Wall Street Zen - Defense World
Minerva Neurosciences: Q1 Earnings Snapshot - CT Insider
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
NERV's Cash Reserves Decrease by $4.1 Million in Q1 2025 | NERV Stock News - GuruFocus
Minerva Neurosciences Reports First Quarter 2025 Financial Resul - GuruFocus
MINERVA NEUROSCIENCES Earnings Results: $NERV Reports Quarterly Earnings - Nasdaq
Minerva Neurosciences, Inc. SEC 10-Q Report - TradingView
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com - Defense World
Minerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Renaissance Technologies LLC Has $285,000 Stock Holdings in Minerva Neurosciences, Inc. (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World
Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - The AM Reporter
CLASS ACTION UPDATE for TILE, NERV and QSR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
CLASS ACTION UPDATE for BABA, NAK and NERV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
Minerva Neurosciences stock hits 52-week low at $1.29 - Investing.com Australia
Minerva Neurosciences stock hits 52-week low at $1.29 By Investing.com - Investing.com South Africa
Major depressive disorder Drugs Market 2034: Clinical Trials, - openPR.com
Minerva Neurosciences regains Nasdaq compliance By Investing.com - Investing.com Australia
FINAL DEADLINE ALERT: ROSEN, LEADING AND RESPECTED INVESTOR COUNSEL, Encourages Minerva Neurosciences, Inc. Investors with Large Losses to Secure Counsel Before Important February 8 Deadline – NERV - Business Wire
Minerva Neurosciences regains Nasdaq compliance - Investing.com
Parkinson's Disease Clinical Pipeline | 130+ Companies Advancing the Future of Treatment - openPR
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld MedTech
Minerva Neurosciences Reports Improved 2024 Financials - TipRanks
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Minerva Neurosciences’ (NERV) Neutral Rating Reiterated at HC Wainwright - Defense World
Minerva Neurosciences stock hits 52-week low at $1.7 By Investing.com - Investing.com Australia
Investor Network: Minerva Neurosciences Inc to Host Earnings Call - ACCESS Newswire
Minerva Neurosciences stock hits 52-week low at $1.7 - Investing.com
Minerva Neurosciences Inc to Host Earnings Call - ACCESS Newswire
Minerva Neurosciences: Q4 Earnings Snapshot - CTPost
Hold Rating for Minerva Neurosciences Amidst Uncertainty Over Roluperidone and Financial Constraints - TipRanks
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):